Get started
Author

Hirotoshi Nakano

Observed name: Hirotoshi NAKANO
Observed institution: KM Biologics (Japan)
ORCID: 0000-0003-0248-8188
Observed ORCID: 0000-0003-0248-8188
OpenAlex ID: A5026993624
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot®) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study
2022 · Yuto Nakajima, Eisuke Takami, et al. · Haemophilia · 11
Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice
2024 · Kazuki Shimizu, Yuto Nakajima, et al. · Thrombosis and Haemostasis · 9
Factor X and combined factor VIIa/factor X augment coagulation potential in a plasma model of antithrombin-reduced hemophilia
2025 · Shigeharu Oh, Yuto Nakajima, et al. · Research and Practice in Thrombosis and Haemostasis · 2
Additive effect of factor X on the structure and stability of activated factor VII-induced fibrin clot in hemophilic plasma with inhibitor
2023 · Eisuke Takami, Kohei Hashimoto, et al. · Thrombosis Research · 2
Current status and perspectives of factor VIIa/factor X for hemophilia inhibitor treatment
2023 · Eisuke TAKAMI, Hirotoshi NAKANO, et al. · Japanese Journal of Thrombosis and Hemostasis · 1
PDF
Plasma‐Derived Factor VIIa/Factor X Improves Thrombin Generation Potential in a Plasma Model of Haemophilia A Supplemented With Direct Oral Anticoagulants
2026 · Shigeharu Oh, Yuto Nakajima, et al. · Haemophilia
PB2158 Plasma-derived factor VIIa/factor X improves thrombin generation potential in a plasma model of hemophilia A supplemented with direct oral anticoagulants
2026 · Shigeharu Oh, Yuto Nakajima, et al. · Research and Practice in Thrombosis and Haemostasis
PDF
Factor X and Combined Factor VIIa/Factor X Augment Coagulation Potential in a Plasma Model of Tissue Factor Pathway Inhibitor‐Reduced Haemophilia State
2026 · Shigeharu Oh, Yuto Nakajima, et al. · Haemophilia
Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
2025 · Mitsumasa Osuna, Yuto Nakajima, et al. · Research and Practice in Thrombosis and Haemostasis
Refinement of Replacement Fluid Using Human Serum Albumin Preparation to Enhance Biocompatibility in Therapeutic Plasma Exchange
2025 · Yuki Narita, Yoshitaka Takegawa, et al. · Journal of Clinical Apheresis
PDF
Evaluation of coagulability in a case of hemophilia B with inhibitor treated with factor VIIa/factor X and high-dose recombinant factor VIIa
2023 · Toru NAKAHATA, Eisuke TAKAMI, et al. · Japanese Journal of Thrombosis and Hemostasis
PDF
Works count: 11
Citation count: 25
H-index: 2
I10-index: 1
Year
Topic
Type